Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

Joel B. Nelson, Kirk Chan-Tack, Sean P. Hedican, Scott R. Magnuson, Terry J. Opgenorth, G. Steven Bova, Jonathan W. Simons

Research output: Contribution to journalArticle

Abstract

The potent vasoconstrictor endothelin-1 (ET-1) is at its highest concentration in the normal human ejaculate and is associated with the progression of metastatic prostate cancer. ET-1 protein expression is detected in situ in 14 of 14 primary cancers and 14 of 16 metastatic sites of human prostatic carcinoma. Exogenous ET-1 induces prostate cancer proliferation directly and enhances the mitogenic effects of insulin-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibroblast growth factor, and epidermal growth factor in serum- free conditions in vitro. The ET(A)-selective receptor antagonist A-127722 inhibits ET-1-stimulated growth, but the ET(B)-selective receptor antagonist BQ-788 does not. ET-3, an ET(B)-selective agonist, also had no effect on prostate cancer growth. No specific ET(B)-binding sites could be demonstrated in any established human prostate cancer cell line tested, and ET(B) mRNA, detected by reverse transcription PCR, was reduced. The predominance of ET(B) binding on human benign prostatic epithelial tissue is not present in metastatic prostate cancer by autoradiography. In human prostate cancer progression to metastases, ET-1 and ET(A) expression are retained, whereas ET(B) receptor expression is reduced.

Original languageEnglish (US)
Pages (from-to)663-668
Number of pages6
JournalCancer Research
Volume56
Issue number4
StatePublished - Feb 15 1996

Fingerprint

Endothelin B Receptors
Endothelin-1
Prostatic Neoplasms
Insulin-Like Growth Factor II
Platelet-Derived Growth Factor
Vasoconstrictor Agents
Fibroblast Growth Factor 2
Growth
Autoradiography
Insulin-Like Growth Factor I
Epidermal Growth Factor
Reverse Transcription
Epithelium
Binding Sites
Neoplasm Metastasis
Carcinoma
Cell Line
Polymerase Chain Reaction
Messenger RNA
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nelson, J. B., Chan-Tack, K., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996). Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Research, 56(4), 663-668.

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. / Nelson, Joel B.; Chan-Tack, Kirk; Hedican, Sean P.; Magnuson, Scott R.; Opgenorth, Terry J.; Bova, G. Steven; Simons, Jonathan W.

In: Cancer Research, Vol. 56, No. 4, 15.02.1996, p. 663-668.

Research output: Contribution to journalArticle

Nelson, JB, Chan-Tack, K, Hedican, SP, Magnuson, SR, Opgenorth, TJ, Bova, GS & Simons, JW 1996, 'Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer', Cancer Research, vol. 56, no. 4, pp. 663-668.
Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Research. 1996 Feb 15;56(4):663-668.
Nelson, Joel B. ; Chan-Tack, Kirk ; Hedican, Sean P. ; Magnuson, Scott R. ; Opgenorth, Terry J. ; Bova, G. Steven ; Simons, Jonathan W. / Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. In: Cancer Research. 1996 ; Vol. 56, No. 4. pp. 663-668.
@article{5f2faf0320dd462db2ee51c0bb8e9883,
title = "Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer",
abstract = "The potent vasoconstrictor endothelin-1 (ET-1) is at its highest concentration in the normal human ejaculate and is associated with the progression of metastatic prostate cancer. ET-1 protein expression is detected in situ in 14 of 14 primary cancers and 14 of 16 metastatic sites of human prostatic carcinoma. Exogenous ET-1 induces prostate cancer proliferation directly and enhances the mitogenic effects of insulin-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibroblast growth factor, and epidermal growth factor in serum- free conditions in vitro. The ET(A)-selective receptor antagonist A-127722 inhibits ET-1-stimulated growth, but the ET(B)-selective receptor antagonist BQ-788 does not. ET-3, an ET(B)-selective agonist, also had no effect on prostate cancer growth. No specific ET(B)-binding sites could be demonstrated in any established human prostate cancer cell line tested, and ET(B) mRNA, detected by reverse transcription PCR, was reduced. The predominance of ET(B) binding on human benign prostatic epithelial tissue is not present in metastatic prostate cancer by autoradiography. In human prostate cancer progression to metastases, ET-1 and ET(A) expression are retained, whereas ET(B) receptor expression is reduced.",
author = "Nelson, {Joel B.} and Kirk Chan-Tack and Hedican, {Sean P.} and Magnuson, {Scott R.} and Opgenorth, {Terry J.} and Bova, {G. Steven} and Simons, {Jonathan W.}",
year = "1996",
month = "2",
day = "15",
language = "English (US)",
volume = "56",
pages = "663--668",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

AU - Nelson, Joel B.

AU - Chan-Tack, Kirk

AU - Hedican, Sean P.

AU - Magnuson, Scott R.

AU - Opgenorth, Terry J.

AU - Bova, G. Steven

AU - Simons, Jonathan W.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - The potent vasoconstrictor endothelin-1 (ET-1) is at its highest concentration in the normal human ejaculate and is associated with the progression of metastatic prostate cancer. ET-1 protein expression is detected in situ in 14 of 14 primary cancers and 14 of 16 metastatic sites of human prostatic carcinoma. Exogenous ET-1 induces prostate cancer proliferation directly and enhances the mitogenic effects of insulin-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibroblast growth factor, and epidermal growth factor in serum- free conditions in vitro. The ET(A)-selective receptor antagonist A-127722 inhibits ET-1-stimulated growth, but the ET(B)-selective receptor antagonist BQ-788 does not. ET-3, an ET(B)-selective agonist, also had no effect on prostate cancer growth. No specific ET(B)-binding sites could be demonstrated in any established human prostate cancer cell line tested, and ET(B) mRNA, detected by reverse transcription PCR, was reduced. The predominance of ET(B) binding on human benign prostatic epithelial tissue is not present in metastatic prostate cancer by autoradiography. In human prostate cancer progression to metastases, ET-1 and ET(A) expression are retained, whereas ET(B) receptor expression is reduced.

AB - The potent vasoconstrictor endothelin-1 (ET-1) is at its highest concentration in the normal human ejaculate and is associated with the progression of metastatic prostate cancer. ET-1 protein expression is detected in situ in 14 of 14 primary cancers and 14 of 16 metastatic sites of human prostatic carcinoma. Exogenous ET-1 induces prostate cancer proliferation directly and enhances the mitogenic effects of insulin-like growth factor I, insulin-like growth factor II, platelet-derived growth factor, basic fibroblast growth factor, and epidermal growth factor in serum- free conditions in vitro. The ET(A)-selective receptor antagonist A-127722 inhibits ET-1-stimulated growth, but the ET(B)-selective receptor antagonist BQ-788 does not. ET-3, an ET(B)-selective agonist, also had no effect on prostate cancer growth. No specific ET(B)-binding sites could be demonstrated in any established human prostate cancer cell line tested, and ET(B) mRNA, detected by reverse transcription PCR, was reduced. The predominance of ET(B) binding on human benign prostatic epithelial tissue is not present in metastatic prostate cancer by autoradiography. In human prostate cancer progression to metastases, ET-1 and ET(A) expression are retained, whereas ET(B) receptor expression is reduced.

UR - http://www.scopus.com/inward/record.url?scp=0030047858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030047858&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 663

EP - 668

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -